Medicines that reduce morbimortality in patients with heart failure: A literature review
DOI:
https://doi.org/10.33448/rsd-v13i2.45141Keywords:
Heart failure; Medications; Morbimortality; Cardiology; Treatment.Abstract
The Heart failure (HF) is a condition characterized by the heart's inability to pump or accommodate blood efficiently, leading to symptoms resulting from decreased cardiac output and elevated filling pressures. Its treatment aims to alleviate symptoms, improve quality of life, address the underlying cause, and reduce morbidity and mortality. HF-related mortality is significant, around 50% within 5 years, along with high rates of hospitalization and readmission. Given the significant morbidity and mortality associated with heart failure, the aim of this study was precisely to conduct an integrated review of available databases to better explore the theme of which drugs used in its therapeutic arsenal are capable of reducing its morbidity and mortality and by what mechanisms this occurs. Recent studies have investigated the impact of available medications in managing HF, highlighting the effectiveness of SGLT2 co-transporter inhibitors, beta-blockers, renin-angiotensin-aldosterone system blockers, and neprilysin inhibitors and angiotensin receptor blockers in reducing morbidity and mortality. The synergy between these classes of medications, individualization of treatment, and continuous education of healthcare professionals on the subject are essential to optimize clinical outcomes and increase survival in these HF patients.
References
Albuquerque, D. C. de, Souza Neto, J. D., Bacal, F., Rohde, L. E. P., Bernardez-Pereira, S., Berwanger, O., & Almeida, D. R. (2015). I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. Arquivos Brasileiros de Cardiologia. https://doi.org/10.5935/abc.20150031LBUQUERQUE DC, et al. I registro brasileiro de insuficiência cardíaca–aspectos clínicos, qualidade assistencial e desfechos hospitalares. Arquivos Brasileiros de Cardiologia, 2015; 104: 433-442
Almeida, D. J. (2020). Patologias associadas ao consumo abusivo de álcool. Relatório de Estágio e Monografia, Universidade de Coimbra. Estudogeral.uc.pt. https://estudogeral.uc.pt/handle/10316/93047
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., & Ponikowski, P. (2021). Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16). https://doi.org/10.1056/nejmoa2107038
Chaudhary, R., Garg, J., Krishnamoorthy, P., Shah, N., Lanier, G., Martinez, M. W., & Freudenberger, R. (2016). Ivabradine: Heart Failure and Beyond. Journal of Cardiovascular Pharmacology and Therapeutics, 21(4), 335–343. https://doi.org/10.1177/1074248415624157
Cleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J., Coats, A. J. S., Manzano, L., McMurray, J. J. V., Ruschitzka, F., van Veldhuisen, D. J., von Lueder, T. G., Böhm, M., Andersson, B., Kjekshus, J., Packer, M., Rigby, A. S., Rosano, G., Wedel, H., Hjalmarson, Å., & Wikstrand, J. (2018). Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 39(1), 26–35. https://doi.org/10.1093/eurheartj/ehx564
Darden, D., Drazner, M. H., Mullens, W., Dupont, M., Tang, W., & Grodin, J. L. (2019). Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. Clinical Cardiology, 42(10), 1010–1018. https://doi.org/10.1002/clc.23260
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., & Zinman, B. (2019). Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME. Trial. Circulation, 139(11), 1384–1395. https://doi.org/10.1161/circulationaha.118.037778
Fukuta, H., Goto, T., Wakami, K., & Ohte, N. (2017). Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Heart Failure Reviews, 22(6), 775–782. https://doi.org/10.1007/s10741-017-9637-0
Koenigsberger, D., Marquez, A., Hughes, P. R. (2021). Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes? The Journal of Family Practice, 70(6). https://doi.org/10.12788/jfp.0235
Kotecha, D., Flather, M. D., Altman, D. G., Holmes, J., Rosano, G., Wikstrand, J., Packer, M., Coats, A. J. S., Manzano, L., Böhm, M., Veldhuisen, D. J. van, Andersson, B., Wedel, H., Lueder, T. G. von, Rigby, A. S., Hjalmarson, Å., Kjekshus, J., Cleland, J. G. F., & Group, B.-B. in H. F. C. (2017). Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. Journal of the American College of Cardiology, 69(24), 2885–2896. https://doi.org/10.1016/j.jacc.2017.04.001
Lakatos, E. M., Marconi, M. A (2017). Fundamentos de metodologia científica I (Vol. 08). Editora Atlas
Lam, P. H., Dooley, D. J., Fonarow, G. C., Butler, J., Bhatt, D. L., Filippatos, G. S., Deedwania, P., Forman, D. E., White, M., Fletcher, R. D., Arundel, C., Blackman, M. R., Adamopoulos, C., Kanonidis, I. E., Aban, I. B., Patel, K., Aronow, W. S., Allman, R. M., Anker, S. D., & Pitt, B. (2017). Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. European Journal of Heart Failure, 20(2), 359–369. https://doi.org/10.1002/ejhf.937
Lund, L. H., Claggett, B., Liu, J., Lam, C. S., Jhund, P. S., Rosano, G. M., Swedberg, K., Yusuf, S., Granger, C. B., Pfeffer, M. A., McMurray, J. J. V., Solomon, S. D. (2018). Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 20(8), 1230–1239. https://doi.org/10.1002/ejhf.1149
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R. (2014). Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 371(11), 993–1004. https://doi.org/10.1056/nejmoa1409077
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., & Howlett, J. G. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21). https://doi.org/10.1056/nejmoa1911303
Morrow, D. A., Velazquez, E. J., DeVore, A. D., Desai, A. S., Duffy, C. I., Ambrosy, A. P., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019). Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF. Trial. Circulation, 139(19), 2285–2288. https://doi.org/10.1161/circulationaha.118.039331
Narayanan, M. A., Reddy, Y. N. V., Baskaran, J., Deshmukh, A., Benditt, D. G., & Raveendran, G. (2017). Ivabradine in the treatment of systolic heart failure - A systematic review and meta-analysis. World Journal of Cardiology, 9(2), 182–190. https://doi.org/10.4330/wjc.v9.i2.182
Nunes, L. C., Henriques, M. F., Brito, M. L. V. de L., Oliveira, C. R. V., & Reis, B. C. C. (2022). Associação dos inibidores do cotransportador SGLT2 ao tratamento de insuficiência cardíaca: uma revisão de literatura. Revista Eletrônica Acervo Médico, 10, e10336. https://doi.org/10.25248/reamed.e10336.2022
Ouwerkerk, W., Teng, T. K., Tromp, J., Tay, W. T., Cleland, J. G., Veldhuisen, D. J., Dickstein, K., Ng, L. L., Lang, C. C., Anker, S. D., Zannad, F., Hung, C., Sawhney, J. P. S., Naik, A., Shimizu, W., Hagiwara, N., Wander, G. S., Anand, I., Richards, A. M., & Voors, A. A. (2020). Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries. European Journal of Heart Failure, 22(8), 1472–1482. https://doi.org/10.1002/ejhf.1869 .
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., & Chuquiure, E. (2020). Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383(15). https://doi.org/10.1056/nejmoa2022190 .
Pfeffer, M. A., Braunwald, E. (2016). Treatment of Heart Failure With Preserved Ejection Fraction. Reflections on Its Treatment With an Aldosterone Antagonist. JAMA Cardiology, 1(1), 7. https://doi.org/10.1001/jamacardio.2015.0356
Pfeffer, M. A., Claggett, B., Assmann, S. F., Boineau, R., Anand, I. S., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., Heitner, J. F., Lewis, E. F., O’Meara, E., Rouleau, J.-L., Probstfield, J. L., Shaburishvili, T., Shah, S. J., Solomon, S. D., Sweitzer, N. K., & McKinlay, S. M. (2015). Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation, 131(1), 34–42. https://doi.org/10.1161/CIRCULATIONAHA.114.013255
Prins, K. W., Neill, J. M., Tyler, J. O., Eckman, P. M., & Duval, S. (2015). Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC. Heart Failure, 3(8), 647–653. https://doi.org/10.1016/j.jchf.2015.03.008
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N. O., Albuquerque, D. C. de, Rassi, S., Colafranceschi, A. S., Freitas Junior, A. F. de, Ferraz, A. S., Biolo, A., Barretto, A. C. P., Ribeiro, A. L. P., Polanczyk, C. A., Gualandro, D. M., Almeida, D. R., Silva, E. R. R. da, Figueiredo, E. L., Mesquita, E. T., Marcondes-Braga, F. G., & Cruz, F. das D. da. (2018). Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arquivos Brasileiros de Cardiologia, 111(3). https://doi.org/10.5935/abc.20180190
Salah, H. M., Fudim, M., Al’Aref, S. J., Khan, M. S., Almarzooq, Z. I., Devabhaktuni, S. R., Mentz, R. J., Butler, J., & Greene, S. J. (2021). Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 145, 165–168. https://doi.org/10.1016/j.amjcard.2021.01.013
Sinha, B., & Ghosal, S. (2019). Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Research and Clinical Practice, 150, 8–16. https://doi.org/10.1016/j.diabres.2019.02.014
Snyder, H. (2019). Literature Review as a Research methodology: an Overview and Guidelines. Journal of Business Research, 104(1), 333–339. ScienceDirect. https://doi.org/10.1016/j.jbusres.2019.07.039
Solomon, S. D., Claggett, B., Desai, A. S., Packer, M., Zile, M., Swedberg, K., Rouleau, J. L., Shi, V. C., Starling, R. C., Kozan, Ö., Dukat, A., Lefkowitz, M. P., & McMurray, J. J. V. (2016). Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. Circulation: Heart Failure, 9(3). https://doi.org/10.1161/circheartfailure.115.002744
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., & Comin-Colet, J. (2019). Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 381(17), 1609–1620. https://doi.org/10.1056/nejmoa1908655
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., & Fang, J. C. (2022). Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206286
Stolfo, D., Uijl, A., Benson, L., Schrage, B., Marat Fudim, Asselbergs, F. W., Koudstaal, S., Sinagra, G., Ulf Dahlström, Rosano, G., & Savarese, G. (2019). Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 22(1), 103–112. https://doi.org/10.1002/ejhf.1615
Tamaki, Y., Yaku, H., Morimoto, T., Inuzuka, Y., Ozasa, N., Yamamoto, E., Yoshikawa, Y., Miyake, M., Kondo, H., Tamura, T., Kitai, T., Iguchi, M., Nagao, K., Nishikawa, R., Kawase, Y., Morinaga, T., Kawato, M., Toyofuku, M., Sato, Y., & Kuwahara, K. (2021). Lower In‐Hospital Mortality With Beta‐Blocker Use at Admission in Patients With Acute Decompensated Heart Failure. Journal of the American Heart Association, 10(13). https://doi.org/10.1161/jaha.120.020012
Vaduganathan, M., Claggett, B. L., Jhund, P. S., Cunningham, J. W., Pedro Ferreira, J., Zannad, F., Packer, M., Fonarow, G. C., McMurray, J. J. V., & Solomon, S. D. (2020). Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet, 396(10244), 121–128. https://doi.org/10.1016/S0140-6736(20)30748-0
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., Johnson, M. R., Kasper, E. K., Levy, W. C., Masoudi, F. A., McBride, P. E., McMurray, J. J. V., Mitchell, J. E., Peterson, P. N., Riegel, B., & Sam, F. (2013). 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 128(16). https://doi.org/10.1161/cir.0b013e31829e8776
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Felipe Alves Soares; Alessandro Reis
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.